Production (Stage)
BioXcel Therapeutics, Inc.
BTAI
$1.39
$0.021.46%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 72.92% | 51.21% | 72.96% | 84.49% | 49.26% |
| Total Depreciation and Amortization | -2.56% | -1.28% | -2.53% | -4.94% | -2.50% |
| Total Amortization of Deferred Charges | 713.95% | -27.69% | -71.88% | -73.03% | -87.09% |
| Total Other Non-Cash Items | -177.38% | -468.31% | -134.41% | -258.99% | -15.82% |
| Change in Net Operating Assets | -137.07% | 146.79% | -116.65% | -161.48% | 176.99% |
| Cash from Operations | 31.98% | 44.87% | 56.53% | 39.34% | 66.18% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -47.63% | 194.78% | -- | 2,090.40% | 7.34% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -586.32% | 28.97% | -- | -- | 84.17% |
| Cash from Financing | -50.42% | 101.41% | -- | 2,021.60% | 10.26% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -87.01% | 57.43% | 57.74% | 52.94% | 131.63% |